{"name":"Charitable Union for the Research and Education of Peyronie's Disease","slug":"charitable-union-for-the-research-and-education-of-peyronie-s-disease","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CCH administration","genericName":"CCH administration","slug":"cch-administration","indication":"Peyronie's disease with penile curvature deformity","status":"marketed"},{"name":"Control - Crossover to CCH","genericName":"Control - Crossover to CCH","slug":"control-crossover-to-cch","indication":"Peyronie's disease with penile curvature deformity","status":"marketed"}]}],"pipeline":[{"name":"CCH administration","genericName":"CCH administration","slug":"cch-administration","phase":"marketed","mechanism":"CCH (collagenase clostridium histolyticum) is an injectable enzyme that breaks down collagen in penile plaques, reducing curvature and improving erectile function in Peyronie's disease.","indications":["Peyronie's disease with penile curvature deformity"],"catalyst":""},{"name":"Control - Crossover to CCH","genericName":"Control - Crossover to CCH","slug":"control-crossover-to-cch","phase":"marketed","mechanism":"This is a crossover study comparing a control arm to collagenase clostridium histolyticum (CCH) treatment for Peyronie's disease.","indications":["Peyronie's disease with penile curvature deformity"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}